glp-1-drugs-and-appeals">Humana Diabetes Supplies Denied: CGM, Insulin Pumps, GLP-1 Drugs, and Appeals

Diabetes management requires a range of supplies and medications — continuous glucose monitors, insulin pumps, test strips, lancets, and increasingly GLP-1 receptor agonist medications — that are subject to frequent Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization denials and coverage disputes with Humana. Understanding exactly what Humana covers, under which benefit category, and what criteria it applies is essential to winning an appeal.

Continuous Glucose Monitor (CGM) Coverage

Continuous glucose monitors like the Dexcom G7, Abbott FreeStyle Libre 3, and Medtronic Guardian are covered by Humana but subject to prior authorization criteria that have evolved significantly in recent years.

Humana's CGM coverage criteria (which align with Medicare's expanded CGM coverage under the 2023 CMS rule) generally include:

• Diagnosis of diabetes mellitus (Type 1 or Type 2)
• Insulin use (for traditional Medicare criteria) or, under expanded criteria, being on anti-diabetic therapy with significant hypoglycemia history
• Prescription from a treating endocrinologist or primary care physician with documentation of the clinical need

Medicare CGM Update (2023): CMS significantly expanded Medicare CGM coverage in 2023, removing the requirement that beneficiaries be on insulin-requiring therapy and extending coverage to all diabetic beneficiaries for whom CGM monitoring is clinically appropriate. Humana Medicare Advantage plans must cover at minimum what original Medicare covers. If Humana is applying the older, stricter insulin-use requirement to a Medicare Advantage member, that may be grounds for appeal citing CMS's updated coverage determination.

CGM supplies (transmitters, sensors, receivers) are generally covered as DME under your health benefit, not as pharmacy benefit. Make sure your physician is billing under the correct benefit category and using the appropriate HCPCS codes.

Insulin Pump Prior Authorization

Insulin pumps — also called Continuous Subcutaneous Insulin Infusion (CSII) devices — require prior authorization from Humana. Key criteria typically include:

• Type 1 diabetes diagnosis
• Documentation that multiple daily injections are inadequate for glycemic control, OR that the patient's lifestyle or work requirements make pump therapy medically necessary
• Prescribing physician attestation and training plan for the patient in pump use
• For Medicare Advantage members: adherence to CMS Local Coverage Determination (LCD) criteria applicable to your geographic area

Insulin pump supplies (infusion sets, reservoirs, cartridges) require separate coverage authorization from the pump itself. Denials for supplies often occur when supply quantities exceed what Humana's guidelines consider standard, or when the supplier doesn't have a current authorization on file.

ozempic-wegovy-mounjaro-zepbound">GLP-1 Receptor Agonists: Ozempic, Wegovy, Mounjaro, Zepbound

The GLP-1 class of medications has become one of the most contentious drug coverage areas in health insurance. Humana's formulary treatment of these drugs varies significantly based on the indication:

For Type 2 diabetes (Ozempic/semaglutide, Mounjaro/tirzepatide): GLP-1 agonists prescribed specifically for Type 2 diabetes management are more likely to be on Humana's formulary, though often at a higher tier (Tier 3 or 4) requiring prior authorization. Humana PA criteria for diabetes GLP-1s typically require documentation of Type 2 diabetes diagnosis, current HbA1c, and why this drug class is appropriate compared to lower-cost alternatives.

For weight loss (Wegovy/semaglutide, Zepbound/tirzepatide): The same drug molecules approved specifically for chronic weight management face a much harder road with Humana. Many Humana commercial employer plans exclude weight loss medications entirely. Even where covered in principle, prior authorization for Wegovy and Zepbound typically requires:

• BMI of 30 or greater (or 27+ with an obesity-related comorbidity)
• Documentation of prior weight loss attempts
• Absence of contraindications (certain heart conditions, history of pancreatitis, etc.)
• A treating physician's documentation of the obesity management plan

For Medicare Advantage members: As of 2026, Medicare Part D does not cover drugs used exclusively for weight loss (by statute). However, Ozempic (approved for diabetes) can be covered under Part D for diabetic members. Wegovy's coverage under Medicare Part D has been the subject of ongoing legislative and regulatory activity. Check current CMS guidance for the latest on GLP-1 coverage under Medicare.

Humana Pharmacy and specialty tier: GLP-1 agonists are typically placed on Humana's specialty or non-preferred brand tier, which can mean costs of $500+ per month without coverage or inadequate coverage. A tier exception request — arguing that lower-tier alternatives are contraindicated or insufficient — is the primary appeal mechanism.

Diabetes Test Strips and Lancets

Blood glucose monitoring supplies (test strips, lancets, meters) are covered under your DME benefit for Medicare Advantage members and your medical benefit for many commercial plans. Coverage quantities are limited:

• Standard coverage: 100 test strips and 100 lancets per month for insulin-using members
• Reduced quantities: 100 strips per 3 months for non-insulin-using members (original Medicare standard)

If you require more supplies than the standard quantity — documented by your physician as medically necessary due to intensive insulin management, hypoglycemia unawareness, or other clinical factors — a prior authorization request for enhanced quantities can be supported with your physician's documentation.

How to Appeal Humana Diabetes Supply Denials

Step 1: Confirm the denial basis — is it a coverage/formulary issue, a prior authorization issue, a quantity limit, or a billing/benefit category issue?

Step 2: Have your endocrinologist or primary care physician document the clinical necessity with specifics:

• Current HbA1c and hypoglycemia history
• Insulin management regimen
• Why the specific device or drug is appropriate for your case
• What lower-cost or formulary alternatives were tried and their outcomes

Step 3: For GLP-1 PA denials, document that lower-tier alternatives (metformin, sulfonylureas, DPP-4 inhibitors, etc.) were tried and failed or are contraindicated.

Step 4: For Medicare Advantage CGM denials, cite the 2023 CMS expanded CGM coverage determination.

Step 5: File your appeal:

• MyHumana portal at humana.com
• Phone: 1-800-457-4708
• Mail: Humana Grievances and Appeals, P.O. Box 14546, Lexington, KY 40512

Fight Back With ClaimBack

Diabetes supply and medication denials from Humana are common — but they are frequently overturned with the right clinical documentation. ClaimBack helps you build the appeal letter that presents the strongest possible case.

Start your appeal at https://claimback.app/appeal.

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeal